Menu Display

Breadcrumb

Media

U.S. News Room

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to jennifer.brennan@daiichisankyo.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

August 27, 2026 NEW
DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo Download
August 26, 2026 NEW
TROPION-Urothelial04 Phase 3 Trial of Datroway Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer Download
August 24, 2026 NEW
Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio Download
August 17, 2026 NEW
Enhertu Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial Download
May 28, 2026
Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO Download
May 22, 2026
Datroway Approved in the US as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates Download
May 15, 2026
Enhertu Approved in the US for Two New Indications for Patients with HER2 Positive Early Breast Cancer Download
May 11, 2026
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation Download
April 13, 2026
Ifinatamab Deruxtecan Granted Priority Review in the US for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy Download
March 09, 2026
ENHERTU Granted Priority Review in the US as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer Download
March 09, 2026
Patent Dispute Between Daiichi Sankyo and Seagen has Concluded
February 19, 2026
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D Download
February 04, 2026
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo Download
February 03, 2026
DATROWAY Granted Priority Review in the US as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy Download
January 13, 2026
TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer Download
December 22, 2025
ENHERTU Granted Breakthrough Therapy Designation in the US as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer Download
December 22, 2025
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer Download
December 15, 2025
ENHERTU Plus Pertuzumab Approved in the US as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer Download
December 09, 2025
DESTINY-Ovarian01 Phase 3 Trial of ENHERTU Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer Download
December 08, 2025
Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS Download
Page 1 of 11
20 Items per Page
Showing 1 - 20 of 203 results.